
Medical AI company
Mediwhale
Seoul-based developer of Dr. Noon, retinal-image AI that estimates cardiovascular, kidney and eye disease risk.
Company overview
Mediwhale develops AI software medical devices that analyse retinal photographs. Dr. Noon CVD estimates future cardiovascular disease risk from retinal images, and Dr. Noon Fundus addresses eye disease findings. The company states Dr. Noon CVD is reimbursed in Korea and commercialized in Dubai, the UK and Italy.
- Headquarters
- Seoul, South Korea
- Company type
- AI Technology Developer
In its own words: “Mediwhale develops AI medical devices that analyze retinal images to predict cardiovascular, kidney, and eye disease risks early.” source
AI products and platforms
- Dr. Noon CVDAI-powered
AI software estimating future cardiovascular disease risk from retinal images
Product page ↗ - Dr. Noon FundusAI-powered
AI analysis of fundus images for eye disease
Product page ↗
Technology categories
Clinical applications
- health screening
- cardiovascular risk assessment
Markets served
- South Korea
- United Arab Emirates
- United Kingdom
- Italy
Regulatory information
- Dr. Noon CVD Korea MFDS approval, licence 제허 22-513호 (initial approval 1 August 2022) source
- Dr. Noon CVD EC certificate KR21/81826550 issued by SGS Belgium NV source
As stated by the company or the cited regulator page. Authorisation is specific to a product, version and market; confirm the current status with the company and the regulator. About medical device regulation
Official sources
Last verified 29 October 2026 against the sources above.
Questions about Mediwhale
Does Medical AI have to explain how it reaches its outputs?
Not always in a technical sense, but transparency about the product is increasingly expected. Many machine learning models cannot give a simple step-by-step reason for each output, so regulators focus on clear information for users: intended use, inputs, how the model was developed and tested, performance, and known limitations.
In the US, one of the criteria for clinical decision support to fall outside device regulation is that a healthcare professional can independently review the basis for its recommendations. FDA has also published transparency principles for machine learning devices with Health Canada and MHRA.
For buyers, a vendor's ability to document how its model works and where it fails is often more useful than heat maps or confidence scores alone.
How is AI used with ECGs from wearables and remote monitors?
AI is used to screen large volumes of ECG data from patches, wearables and remote monitors, flagging possible arrhythmias or recordings that need clinician review. This helps manage the large amount of data produced by continuous monitoring.
Important distinctions for buyers:
- A consumer feature on a wearable and a clinical-grade analysis service can have very different intended uses and authorizations.
- Authorization often covers specific recording hardware, leads and populations.
- Signal quality and motion artifacts affect results.
In the US, software that analyzes physiological signals does not meet the criteria for non-device CDS. Confirm each product's status, and check how alerts are routed to clinicians and documented.
What is AI image reconstruction and denoising?
AI image reconstruction and denoising use deep learning to produce clearer images from raw scanner data or to reduce noise and artifacts, for example in CT or MRI. Vendors often position these tools as supporting lower-dose or faster scanning protocols.
Unlike detection software, these tools change the image the clinician reads rather than adding a finding. Questions to ask include:
- Is the function built into the scanner or a separate software product?
- Which scanners, protocols and body regions is it authorized for?
- How was diagnostic image quality evaluated, and could fine detail be lost or altered?
These functions are typically regulated as part of the imaging device or as image processing software, depending on the product and market.